Medpace (NASDAQ:MEDP) Director Sells $690,121.80 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Cornelius Mccarthy III sold 1,140 shares of Medpace stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total value of $690,121.80. Following the completion of the transaction, the director owned 12,275 shares in the company, valued at approximately $7,430,916.75. This represents a 8.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Medpace Trading Down 0.6%

Shares of NASDAQ MEDP opened at $578.50 on Friday. The company has a market cap of $16.15 billion, a price-to-earnings ratio of 33.91, a PEG ratio of 2.58 and a beta of 1.15. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The stock has a 50-day moving average price of $536.23 and a two-hundred day moving average price of $492.35.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period last year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on MEDP shares. Royal Bank Of Canada boosted their target price on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. BMO Capital Markets increased their price target on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Barclays set a $600.00 price objective on Medpace in a research report on Thursday, July 23rd. Finally, Leerink Partners set a $620.00 target price on Medpace in a report on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $584.18.

Institutional Investors Weigh In On Medpace

A number of institutional investors have recently added to or reduced their stakes in the business. Johnson Financial Group Inc. bought a new position in shares of Medpace during the second quarter valued at $27,000. Geneos Wealth Management Inc. grew its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Elyxium Wealth LLC bought a new stake in shares of Medpace in the fourth quarter worth $30,000. Jones Financial Companies Lllp acquired a new stake in Medpace in the second quarter valued at $30,000. Finally, Allied Private Wealth LLC acquired a new stake in Medpace in the second quarter valued at $31,000. 77.98% of the stock is owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.